SPA
RCKT icon

Sherbrooke Park Advisers’s Rocket Pharmaceuticals RCKT Stock Holding History

Sherbrooke Park Advisers’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-23,193
Closed -$292K – 874
2024
Q4 		$292K Buy
+23,193
New +$349K 0.09% 418

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sherbrooke Park Advisers's RCKT Position: Q1 2025 in Review

Sherbrooke Park Advisers sold out of Rocket Pharmaceuticals (RCKT) in Q1 2025, closing a stake of 23,193 shares — an estimated $292K sold.

Sherbrooke Park Advisers first reported a position in RCKT in Q4 2024 and held it in 1 quarter. The position peaked at $292K in Q4 2024. 236 funds tracked by Wall St. Rank hold RCKT as of Q1 2025.

  • Sherbrooke Park Advisers reported no remaining Rocket Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 23,193 Rocket Pharmaceuticals shares in Q1 2025, an estimated $292K.
  • Sherbrooke Park Advisers first reported a position in Rocket Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Sherbrooke Park Advisers's Rocket Pharmaceuticals position peaked at $292K in Q4 2024.
  • 236 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q1 2025, filed 15 May 2025.